Summary of Patient Characteristics, Imaging Data, and Follow-up
| Receptor expression* | Endocrine treatment | 99mTc-Depreotide uptake | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Age (y) | Date† | ER (%) | PgR (%) | Type | Indication | Disease site(s) | Baseline | Change baseline follow-up‡ | PFI (mo) | Follow-up |
| 1 | 74 | 2000 | 90 | 30 | tam→AI | Diagnosis M+ | Bone | Negative | NA | 0 | NR |
| 2 | 74 | 1997 | 0 | 0 | tam→AI | Progression | Bone, pleura | Negative | NA | 0 | NR |
| 3 | 74 | 2002 | 100 | 100 | tam | Diagnosis M+ | Liver, bone | Negative | NA | 3 | NR |
| 4 | 72 | 2001 | ++ | + | AI | Diagnosis M+ | Bone | Negative | NA | 0 | NR |
| 5 | 59 | 2000 | 30 | 50 | AI | Stabilization after CT | Bone, liver | Negative | NA | 0 | NR |
| 6 | 54 | 1999 | 90 | 90 | AI→FA | Progression | Bone, liver, soft tissue | Negative | NA | 0 | NR |
| 7 | 69 | 1999 | 98 | 99 | tam→AI | Progression | Bone, pleura | Negative | NA | 0 | NR |
| 8 | 52 | 2002 | 0 | <5 | tam→AI | Progression | Soft tissue | Positive | ↑ (+116%) | 3 | NR |
| 9 | 60 | 1997 | 95 | 68 | tam→AI | Progression | Bone, liver, pleura, lung | Positive | ↑ (+29%) | 0 | NR |
| 10 | 46 | 2002 | 70 | 50 | AI | Diagnosis M+ | Bone, liver | Positive | ↑ (+63%)/ = (5%) | 0 | NR |
| 11 | 61 | 1985 | (+) | (+) | tam | Diagnosis M+ | Bone | Positive | ↓ (−42%) | 31 | R |
| 12 | 75 | 2002 | 95 | 5 | AI | First diagnosis | Breast, skin | Positive | ↓ (−33%) | 16§ | R |
| 13 | 53 | 2001 | 80 | 0 | tam | Stabilization after CT | Liver | Positive | = (+1%) | 12 | R |
| 14 | 76 | 2000 | 90 | 40 | tam→AI | Progression | Bone | Positive | = (−4%) | 22§ | R |
| 15 | 57 | 1996 | 100 | 20 | tam | Diagnosis M+ | Bone | Positive | = (+5%) | 14 | R |
| 16 | 56 | 1997 | 100 | 10 | AI | Progression | Bone, pleura | Positive | ↓ (−50%)/ = (+4%) | 11§ | R |
| 17 | 59 | 2002 | 100 | 100 | tam→AI | Progression | Bone, breast | Positive | ↓ (−29%)/ = (−15%) | 11§ | R |
| 18 | 59 | 1996 | 80 | 10 | tam→AI | Diagnosis M+ | Bone | Positive | Only baseline scan | 12 | R |
↵* Evaluation of hormone receptor status was performed using IHC, except for patient 11, where LBA was applied. Immunostaining scores: percentage of positively stained cells or −, negative; (+), weakly positive; +, intermediately positive; ++, strongly positive.
↵† Most recent biopsy.
↵‡ Mean percentage change in all lesions per group. Groups: ↑, increase in uptake of >25%; =, increase or decrease in uptake of ≤25%; ↓, decrease in uptake of >25%.
↵§ Still responding at conclusion of study.
tam = tamoxifen; AI = aromatase inhibitor; FA = full antagonist of ER (fulvestrant); M+ = metastasis; CT = chemotherapy; NA = not applicable; PFI = progression-free interval; NR = nonresponder; R = responder.